Jubilant Generics Receives GST Show Cause Notice for ₹105.5 Crore Demand
Jubilant Generics Limited received a Show Cause Notice from CGST, Roorkee, proposing a demand of ₹52.75 crore GST and ₹52.75 crore penalty for FY21-22. The company contests the notice, citing alleged violation of IGST refund and Advance Authorisation scheme rules. Jubilant expects no financial impact.
While the company expects no financial impact and plans to contest the notice, the demand amount is substantial and pertains to tax and penalties, warranting a medium impact assessment.
The company has received a show cause notice proposing a significant demand for GST, interest, and penalty, which is a negative development.
Jubilant Pharmova Limited announced that its wholly-owned subsidiary, Jubilant Generics Limited, has received a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee. The notice proposes a demand for GST, interest, and penalty amounting to ₹52.75 crore each, totaling ₹105.5 crore, for the financial years 2020-21 and 2021-22.
The dispute pertains to the alleged availment of IGST refund under Rule 96 and the benefit of the Advance Authorisation scheme simultaneously, in violation of Rule 96(10) of CGST Rules, 2017. The notice was issued on August 27, 2026, at 12:35 PM IST.
Jubilant Pharmova stated that the company is in the process of filing a detailed reply before the Joint Commissioner, contesting the demand. The company believes the notice is factually and legally incorrect and has been issued without proper verification. Jubilant Pharmova expects no financial or operational impact from this notice, as they have a strong case in their favor.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.